Aethlon Medical reports Q2 EPS ($3.74) vs. ($16.11) last year

As of September 30, 2025, Aethlon had a cash balance of approximately $5.8M. “We remain focused on executing our clinical and research strategy while maintaining operational discipline,” said James Frakes, CEO and CFO. “Our ongoing trial progress, research collaborations, and technology initiatives continue to support our long-term goal of developing therapeutic solutions for cancer and life-threatening infectious diseases.”